Health
Novo Asks for More Time to Answer Sanders on Ozempic’s Price
- Sanders informed Novo last month of Senate investigation
- Vermont senator had set May 8 deadline for drugmaker’s answers
This article is for subscribers only.
Novo Nordisk A/S is asking for more time to answer questions from US Senator Bernie Sanders on the prices of Ozempic and Wegovy, the company’s blockbuster drugs for diabetes and weight loss.
“We plan to respond to the latest inquiry in a timely manner; however given the tight turnaround requested, we will need additional time to develop our response,” a spokesperson for the Danish drugmaker said Tuesday in an emailed response to questions.